跳到正文
原文
Medical Xpress·· 13 天前精选AI 评分75

GLP-1受体激动剂失败后胃旁路手术是有效的减肥策略

Bariatric surgery is effective rescue strategy after GLP-1 receptor agonist failure

AI 导读

一项发表在《Annals of Surgery》的研究显示,胃旁路手术在GLP-1受体激动剂不耐受或效果不佳的患者中,可实现显著的两年内减肥效果。

推荐理由

研究显示胃旁路手术在GLP-1受体激动剂失败后的有效减肥效果,为肥胖治疗提供新策略。

正文 · AI 翻译

译文尚不完整,完整内容请切换到原文。

surgery
图片来源:Pixabay/CC0 公共领域

Bariatric surgery is associated with clinically meaningful two-year weight loss after semaglutide or tirzepatide intolerance or inadequate response, according to a study published online Nov. 3 in the Annals of Surgery.

Ali Aminian, M.D., from the Cleveland Clinic, and colleagues evaluated two-year weight loss after bariatric surgery among adults with intolerable adverse effects or inadequate weight loss with semaglutide or tirzepatide. The analysis included adults with a body mass index ≥35 kg/m² undergoing Roux-en-Y gastric bypass (RYGB) or sleeve gastrectomy (SG) from 2018 to 2024 (4,661 had no prior exposure [comparator group]; 61 discontinued semaglutide or tirzepatide; 207 had inadequate weight-loss response).

The researchers found that before surgery, the estimated two-year medication-associated weight change was a 1.4% gain in the intolerance group and 1.5% total body weight loss (TBWL) in the inadequate-response group. Following surgery, in the intolerance group, two-year TBWL was 27.9% and 22.7% after RYGB for patients without and with type 2 diabetes, respectively, and 20.1% and 21.6% after SG.

在效果不佳组中,相应的估计分别为 RYGB 27.4% 和 25.8%,SG 为 14.3% 和 14.2%。在对照组中,相应的两年 TBWL 估计分别为 RYGB 33.3% 和 28.7%,SG 为 23.6% 和 19.9%。在效果不佳组中,经过调整的分析显示,RYGB 相较于 SG 两年的 TBWL 更高(32.7% 对 17.8%)。

‘GLP-1 药物已经改变了肥胖症的治疗,但并非对所有人都有效,’Aminian 在声明中说。‘越来越多的患者和他们的医生在问:下一步是什么?我们的研究结果表明,减肥手术可以是下一步。’

两位作者披露了与制药行业的关联。

出版详情

Ali Aminian 等人,Semaglutide 或 Tirzepatide 治疗后的减重手术作为挽救策略,Annals of Surgery (2026). DOI: 10.1097/sla.0000000000007251

期刊信息: Annals of Surgery

谁是幕后推手?

Gaby Clark

Gaby Clark

MA in English, copy editor since 2021 with experience in higher education and health content. Dedicated to trustworthy science news. 全职档案 →

Andrew Zinin

Andrew Zinin

物理学硕士,有研究经验。长期关注科学新闻。在Science X的编辑成功中扮演关键角色。 完整档案 →

© 2026 HealthDay. 所有权利保留。

引用: 胃肠减重手术是GLP-1受体激动剂失败后的有效救援策略(2026年11月6日) 于2026年11月6日从 https://medicalxpress.com/news/2026-11-bariatric-surgery-effective-strategy-glp.html 获取

本文件受版权保护。除为私人研究或学习目的进行的合理处理外,不得复制任何部分。内容仅供参考。

来源:Medical Xpress · medicalxpress.com